Related Experiment Video
Updated: Jun 10, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[Quantification of prame gene transcript in chronic myeloid leukemia]
Zhao-Hui Zhu1, Jun Qian, Jiang Lin
1Department of Hematology, Central Laboratory, Affiliated People Hospital, Jiangsu University, Zhenjiang 212002, Jiangsu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 21, 2010
Summary
Preferentially expressed antigen of melanoma (prame) transcript levels are significantly elevated in chronic myeloid leukemia (CML) patients. Higher prame expression correlates with CML progression and can aid in disease monitoring.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome.
- Preferentially expressed antigen of melanoma (prame) is a gene with potential roles in cell proliferation and differentiation.
Purpose of the Study:
- To analyze the expression level of prame transcript in CML patients.
- To explore the clinical significance and correlation of prame expression with CML progression.
Main Methods:
- Real-time quantitative PCR (RQ-PCR) was employed to measure prame gene transcript levels.
- Bone marrow samples from 30 CML patients and 15 iron deficiency anemia (IDA) patients were analyzed.
Main Results:
- CML patients exhibited significantly higher prame mRNA levels compared to IDA controls (p < 0.001).
- Prame transcript levels strongly correlated with bcr-abl fusion gene transcript levels (r = 0.708, p < 0.001).
- Elevated prame expression was observed in advanced CML phases (AP/BC) compared to the chronic phase (CP) (p = 0.007).
Conclusions:
- Prame gene transcript levels increase with CML disease progression.
- Prame expression serves as a potential biomarker for monitoring CML disease state.
